Leads Biolabs Secures the US FDA’s Orphan Drug Designation for LBL-034 to Treat Multiple Myeloma
Shots:
- The US FDA has granted ODD to LBL-034 for the treatment of multiple myeloma. It is solely developed by Leads Biolabs using its proprietary T cell engager antibody technology platform, LeadsBody
- Leads got IND approvals from the NMPA & FDA in Jul 2023 and began a P-I/II dose escalation/expansion trial of LBL-034 for r/r MM in Nov 2023 across China, the preliminary data of which depicted a favorable safety & strong efficacy. Data will be featured at the ASH 2024
- LBL-034 is a novel bispecific antibody which binds to CD3 on T cells and GPRC5D on cancer cells to enable cancer cells destruction. LBL-034 showed high binding affinity, strong potency & a reduced risk of T cell exhaustion, suggesting best-in-class potential
Ref: PR Newswire | Image: Leads Biolabs
Related News:- Sanofi and Regeneron Reports the EC’s Approval of Dupixent (Dupilumab) for Young Children with Eosinophilic Esophagitis (EoE)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
